Nuliv Science has announced the findings of a new study on its mood and sleep ingredient, Zylaria.
The recent study in the Journal of Biochemistry and Biotechnology examined the effects of three different botanical compositions Xylaria nigripes extract (XE), Xylaria nigripes + Panax notoginseng extract (XPE), and Xylaria nigripes + Panax notoginseng + Cuscuta chinensis extract (XPCE) on γ-Aminobutyric acid (GABA) content, GABA transaminase (GABA-T), Glutamate decarboxylase (GAD), cells viability, and Amyloid-β protein (Aβ) aggregation levels in PC12 neuron cells. PC12 cells synthesise, store, and release norepinephrine and dopamine.
Zylaria is a research project we’ve been working on for years
All three compositions could effectively improve GABA production and also increase the activity of glutamate GAD along with decreased GABA-T activity in PC12 cells in a dose-dependent fashion. Out of the three compositions, the Zylaria (XPCE) composition showed the best holistic neuroprotective and GABA-releasing properties than XE and XPE.
The researcher observed and suggests that the improvement of GABA levels and strong neuroprotective activity makes these novel compositions (XE, XPE, and XPCE) a potent candidate for supporting insomnia, depression, and various neurological conditions.
“Zylaria is a research project we’ve been working on for years, evaluating different formulations for a balance of efficacy and serving size. We’re excited to share publicly our latest research findings,” said Richard Wang, CEO of NuLiv Science.
The company looks forward to continuing its research and development of Zylaria as it is gaining popularity in the market among leading brands for mood and sleep products.
